Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Cardio Diagnostics Holdings Inc (CDIOW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: CDIOW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -18.75% | Avg. Invested days 49 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 3.06 | 52 Weeks Range 0.01 - 0.18 | Updated Date 05/17/2025 |
52 Weeks Range 0.01 - 0.18 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -173463.83% |
Management Effectiveness
Return on Assets (TTM) -43.94% | Return on Equity (TTM) -81.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1605873 |
Shares Outstanding - | Shares Floating 1605873 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Cardio Diagnostics Holdings Inc
Company Overview
History and Background
Cardio Diagnostics Holdings Inc. is focused on developing and commercializing solutions for cardiovascular disease diagnostics. Details on founding year and early milestones are not readily available in standard financial databases but they focus on precision medicine diagnostics.
Core Business Areas
- AI-Driven Diagnostic Tests: Development and commercialization of diagnostic tests that utilize artificial intelligence to improve the detection and management of cardiovascular diseases.
- Precision Medicine Solutions: Offering personalized diagnostic approaches based on individual patient risk profiles and genetic information.
- Electrocardiogram (ECG) Analysis: Using novel algorithms to enhance the accuracy and efficiency of ECG analysis for detecting heart conditions.
Leadership and Structure
Details about the leadership team and organizational structure are not publicly available in detail.
Top Products and Market Share
Key Offerings
- AXIS CAD: A coronary artery disease (CAD) risk assessment test. Market share data specific to Cardio Diagnostics is not readily available. Key competitors include companies offering traditional CAD diagnostic tests and newer AI-driven solutions such as Cleerly and HeartFlow. Revenue data is not publicly available.
- EPIproRS: A genetic-epigenetic clinical test. Competitors include companies that offer similar genetic testing such as Myriad Genetics, GenomeDx and companies focused on cardiovascular genetic risk assessment. Market share and revenue data are not publicly available.
Market Dynamics
Industry Overview
The cardiovascular diagnostics market is growing, driven by an aging population, increasing prevalence of heart disease, and advancements in diagnostic technologies. The market is highly competitive, with many players offering various diagnostic solutions.
Positioning
Cardio Diagnostics is positioned as an innovator in the cardiovascular diagnostics space, leveraging AI and precision medicine to improve patient outcomes. The company's competitive advantage lies in its AI-driven diagnostic platform and focus on personalized medicine.
Total Addressable Market (TAM)
The TAM for cardiovascular diagnostics is substantial, estimated to be in the billions of dollars globally. Cardio Diagnostics is positioned to capture a portion of this market by offering innovative and personalized diagnostic solutions. An exact number for TAM for its specific business is not readily available.
Upturn SWOT Analysis
Strengths
- Innovative AI-driven diagnostic platform
- Focus on precision medicine
- Potential for improved diagnostic accuracy
- Novel combination of ECG analysis and AI
- Strong focus on clinical validation
Weaknesses
- Limited market share
- High R&D costs
- Reliance on regulatory approvals
- Dependence on successful commercialization efforts
- Limited brand recognition compared to established competitors
Opportunities
- Expanding product portfolio
- Partnering with healthcare providers
- Securing regulatory approvals
- Increasing market awareness
- Penetrating international markets
Threats
- Competition from established players
- Technological advancements by competitors
- Changes in regulatory landscape
- Reimbursement challenges
- Economic downturns
Competitors and Market Share
Key Competitors
- Myriad Genetics (MYGN)
- GenomeDx (Exact Sciences - EXAS)
- Cleerly
- HeartFlow
Competitive Landscape
Cardio Diagnostics is competing in a crowded market with established players. Its competitive advantage lies in its AI-driven platform and precision medicine approach, however it is newer and has lower funding compared to competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited because they are relatively new in the space. (Not available).
Future Projections: Future growth projections are not publicly available and would rely on analyst estimates and company guidance. (Not available).
Recent Initiatives: Initiatives center around clinical validation studies, securing partnerships with healthcare providers, and obtaining regulatory approvals.
Summary
Cardio Diagnostics Holdings Inc. is a small, innovative company focused on using AI to improve cardiovascular diagnostics. While their technology shows promise, they face significant challenges including a crowded market, limited resources, and the need for regulatory approvals. Success depends on securing partnerships, achieving commercial success, and demonstrating clinical value. Future outlook depends on navigating competition and continued innovation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
- Market Analysis Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and based on available data. Financial data may be outdated. Readers should consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cardio Diagnostics Holdings Inc
Exchange NASDAQ | Headquaters Chicago, IL, United States | ||
IPO Launch date 2022-01-14 | Co-Founder, CEO & Director Dr. Meeshanthini V. Dogan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://cdio.ai |
Full time employees 13 | Website https://cdio.ai | ||
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.